Amgen owes $406 million for monopolizing cholesterol drug market, US jury says
Source: Reuters
Amgen owes $406 million for monopolizing cholesterol drug market, US jury says
Blake Brittain
Thu, May 15, 2025 at 4:57 PM EDT 1 min read
(Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its cholesterol-reduction drug Repatha at the expense of Regeneron's rival drug Praluent.
The jury agreed with Regeneron that Amgen unlawfully bundled Repatha with two of its blockbuster anti-inflammatory drugs to persuade pharmacy benefit managers to buy it instead of Praluent.
The verdict includes $271.2 million for Regeneron in punitive damages. Amgen said in a statement that it "has always competed fairly and in compliance with the antitrust laws" and "look[s] forward to post-trial proceedings."
-snip-
Read more: https://www.yahoo.com/news/amgen-owes-406-million-monopolizing-205704976.html
= new reply since forum marked as read
Kick in to the DU tip jar?
This week we're running a special pop-up mini fund drive. From Monday through Friday we're going ad-free for all registered members, and we're asking you to kick in to the DU tip jar to support the site and keep us financially healthy.
As a bonus, making a contribution will allow you to leave kudos for another DU member, and at the end of the week we'll recognize the DUers who you think make this community great.